Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicenter, Randomized, Open-Label Study to Assess the Efficacy, Safety, and Tolerability of RBS2418 in Combination With Tremelimumab Plus Durvalumab for Participants With Advanced Unresectable Hepatocellular Carcinoma

NCT07175441 is registered in ClinicalTrials.gov with Riboscience, LLC. as lead sponsor.

NCT NCT07175441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07175441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicenter, Randomized, Open-Label Study to Assess the Efficacy, Safety, and Tolerability of RBS2418 in Combination With Tremelimumab Plus Durvalumab for Participants With Advanced Unresectable Hepatocellular Carcinoma
Lead sponsor
Riboscience, LLC.
Phase
Phase 2
Overall status
Recruiting
Start date
April 10, 2026
Completion date
August 31, 2027
Enrollment
220 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced unresectable hepatocellular carcinoma